GLP-1 drugs like semaglutide are wildly effective for weight loss — until they aren't. Most patients hit a plateau after months of treatment, and no one really knew why at the cellular level. A team at the National Institutes of Health now has a concrete answer: the drug's effect depends on how long neurons in the area postrema can sustain elevated levels of the signaling molecule cAMP.
cAMP: The Intracellular Switch Behind GLP-1 Efficacy
Andrew Lutas, Claire Gao, Michael Krashes and colleagues used a fluorescence imaging technique on living mouse brain tissue to watch what happens inside neurons when semaglutide binds to GLP-1 receptors. What they saw wasn't uniform. "It was not an all or nothing phenomenon," Krashes said. Some cells kept cAMP elevated for minutes; others only saw a temporary spike before the receptors internalized or degraded.
That variability explains why the same dose doesn't work the same way in every patient — and why the effect eventually fades. The drug works only when cAMP stays high in appetite-regulating circuits of the area postrema. Transient spikes don't cut it.
PDE4 Inhibition as a Strategy to Extend Drug Effects
The team then asked: can you force neurons into the sustained state? They inhibited PDE4, the enzyme that naturally degrades cAMP, using the drug roflumilast. Result: neurons shifted toward a sustained cAMP response. The implication is direct — combining a PDE4 inhibitor with a GLP-1 agonist could extend the drug's active window, potentially allowing less frequent dosing and pushing past the plateau that halts further weight loss.
Roflumilast is already approved for COPD, so the pharmacology is well understood. But the NIH team stresses that "finding out will require much more work." Their current method only captures hours of signaling in brain slices. Next steps: tracking intracellular effects over days and weeks in living animals.
Still, this is the first mechanistic explanation for GLP-1 plateaus that points to a druggable target. If the cAMP-PDE4 axis holds up in vivo, we might finally have a way to keep the effects of these drugs from fizzling out — and that changes how we think about long-term obesity treatment.
Source: NIH researchers identify avenue for enhanced GLP-1-induced weight loss
Domain: nih.gov
Comments load interactively on the live page.